Published in Clin Cancer Res on December 15, 2008
A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg (2013) 1.36
A comparison of fine-needle aspiration, core biopsy, and surgical biopsy in the diagnosis of extremity soft tissue masses. Clin Orthop Relat Res (2010) 1.22
Nomograms in oncology: more than meets the eye. Lancet Oncol (2015) 1.21
The surprising outcome of a giant primary mediastinal synovial sarcoma treated with neoadjuvant chemotherapy. J Thorac Dis (2013) 1.08
Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma (2011) 1.07
Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg (2014) 1.05
Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer (2011) 0.95
Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. Ann Surg Oncol (2013) 0.89
Synovial sarcoma of the spine: a case involving paraspinal muscle with extensive calcification and the surgical consideration in treatment. Eur Spine J (2014) 0.86
Synovial sarcoma of the posterior neck : a case report and review of literature. J Korean Neurosurg Soc (2010) 0.84
A probabilistic analysis of completely excised high-grade soft tissue sarcomas of the extremity: an application of a Bayesian belief network. Ann Surg Oncol (2012) 0.82
Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis. Springerplus (2015) 0.82
Biphasic synovial sarcoma of the extremity: quadruple approach of isolated limb perfusion, surgical ablation, adipofascial perforator flap and radiation to avoid amputation. Case Rep Oncol (2011) 0.81
The Role of (18)F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma. Nucl Med Mol Imaging (2014) 0.80
Expression of FGFR3 and FGFR4 and clinical risk factors associated with progression-free survival in synovial sarcoma. Hum Pathol (2013) 0.79
Incidences of Primary Soft Tissue Sarcoma Diagnosed on Extremities and Trunk Wall: A Population-Based Study in Taiwan. Medicine (Baltimore) (2015) 0.78
Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas. Clin Orthop Relat Res (2014) 0.78
Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy. Cancer Med (2014) 0.77
Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis. J Surg Oncol (2014) 0.77
Principles in Management of Soft Tissue Sarcoma. Adv Surg (2015) 0.76
Management of locally advanced primary mediastinal synovial sarcoma. Lung India (2017) 0.75
Multimodality Management of Soft Tissue Tumors in the Extremity. Surg Clin North Am (2016) 0.75
Sarcoma: primary retroperitoneal sarcoma-predicting survival. Nat Rev Clin Oncol (2013) 0.75
GI Synovial Sarcomas. Clin Transl Gastroenterol (2012) 0.75
Clinical outcomes for patients with synovial sarcoma of the hand. Springerplus (2014) 0.75
Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol (2017) 0.75
SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med (1998) 4.18
The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology (2006) 4.14
Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol (1996) 3.85
Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol (2002) 3.60
Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol (2004) 3.28
Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol (2000) 2.67
Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer (2004) 2.46
Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res (2002) 2.41
Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol (2001) 2.29
Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol (2000) 2.22
Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol (2003) 1.94
Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol (2000) 1.91
Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer (1994) 1.84
Management of soft-tissue sarcomas: an overview and update. Lancet Oncol (2000) 1.76
Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg (2007) 1.75
The role of the pathologist in the management of soft tissue sarcomas. World J Surg (1988) 1.64
Synovial sarcoma: the importance of size and location for survival. Clin Orthop Relat Res (2004) 1.56
Validation of the postoperative nomogram for 12-year sarcoma-specific mortality. Cancer (2004) 1.42
Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol (2004) 1.41
Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol (1996) 1.30
Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology (2003) 1.30
Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease. Cancer (1993) 1.19
Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep (2008) 1.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods (2005) 6.23
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol (2005) 4.79
Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med (2006) 4.71
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25
Quality of complication reporting in the surgical literature. Ann Surg (2002) 4.21
Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis. Bioinformatics (2009) 4.21
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn (2005) 4.21
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol (2002) 3.60
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet (2011) 3.41
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov (2012) 3.04
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg (2010) 2.99
Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg (2010) 2.98
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A (2012) 2.89
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg (2004) 2.86
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med (2006) 2.83
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res (2011) 2.74
A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J (2005) 2.71
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol (2008) 2.68
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol (2003) 2.67
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature (2010) 2.65
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol (2011) 2.58
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol (2008) 2.56
Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. J Am Coll Surg (2003) 2.54
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res (2012) 2.52
Adult spermatic cord sarcomas: management and results. Ann Surg Oncol (2003) 2.52
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn (2010) 2.44
EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther (2013) 2.43